Point72 Asset Management L.P. trimmed its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 79.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 317,114 shares of the company's stock after selling 1,189,532 shares during the period. Point72 Asset Management L.P. owned approximately 1.35% of UroGen Pharma worth $3,377,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of UroGen Pharma by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock worth $231,000 after acquiring an additional 969 shares during the last quarter. Rhumbline Advisers raised its stake in UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock valued at $546,000 after purchasing an additional 1,402 shares during the last quarter. MetLife Investment Management LLC raised its stake in UroGen Pharma by 13.6% during the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock valued at $242,000 after purchasing an additional 2,727 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in UroGen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock valued at $996,000 after purchasing an additional 3,024 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in UroGen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock valued at $211,000 after purchasing an additional 3,920 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price for the company. Guggenheim cut their target price on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a research note on Friday. D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Thursday, May 8th. Scotiabank started coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 target price for the company. Finally, The Goldman Sachs Group reduced their target price on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, UroGen Pharma presently has an average rating of "Moderate Buy" and a consensus target price of $27.43.
Get Our Latest Research Report on UroGen Pharma
UroGen Pharma Stock Performance
URGN stock traded up $0.11 during midday trading on Friday, hitting $4.19. The stock had a trading volume of 2,328,338 shares, compared to its average volume of 671,011. The firm has a market capitalization of $193.19 million, a price-to-earnings ratio of -1.33 and a beta of 0.66. UroGen Pharma Ltd. has a 52 week low of $3.42 and a 52 week high of $20.70. The stock has a 50-day simple moving average of $10.18 and a 200 day simple moving average of $10.73. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. As a group, equities research analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.
UroGen Pharma Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Articles
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
